Latest Health News

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

CONNEQT Health has reported a remarkable surge in Pulse device sales, exceeding 200% growth quarter-on-quarter, while advancing its transition to a recurring revenue model through enterprise contracts and consumer subscriptions.

CONNEQT Health Limited reported a strong quarter with over 200% sales growth for its CONNEQT Pulse product and completed a $3.1 million institutional placement, while operational cost reductions support a leaner business model.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

Nutritional Growth Solutions reports improved cash flow and cost savings amid leadership changes, setting the stage for renewed growth in FY26.

Green360 Technologies has made significant strides in commercialising its low-carbon cement product Eco-Clay, delivering successful large-scale trials and securing a robust financial footing heading into 2026.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

Beetaloo Energy Australia Limited reported a solid cash position of $17.96 million at the end of December 2025, supported by $6.8 million in unused financing facilities. The company’s liquidity covers approximately 2.6 quarters of current cash outflows, positioning it well as it awaits the activation of a new $30 million infrastructure facility.

Blue Energy Limited reports steady progress on its Sapphire gas project and awaits key government decisions on additional resource areas, positioning itself strongly in Queensland's evolving energy landscape.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.